Harris & Harris Group, Inc. (Nasdaq:TINY) notes that Amgen and BioVex Group, Inc., today announced the completion of the acquisition of BioVex Group, Inc.
The transaction provides Amgen with BioVex's lead product candidate, OncoVEXGM-CSF, a novel investigational oncolytic vaccine in Phase 3 clinical development that may represent a new approach to treating melanoma and head and neck cancer. The acquisition was initially announced on January 24, 2011.
Harris & Harris Group was an investor in privately held BioVex Group. Harris & Harris Group made its initial investment in BioVex Group in September 2007.
Harris & Harris Group is a publicly traded venture capital company that invests in nanotechnology and microsystems.